A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BKM120 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 20 Jul 2017
At a glance
- Drugs Binimetinib (Primary) ; Buparlisib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Array BioPharma; Novartis
- 17 Jul 2017 Planned End Date changed from 30 Jun 2017 to 31 Dec 2017.
- 10 Jun 2017 Biomarkers information updated
- 24 Nov 2015 Planned End Date changed from 1 Dec 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov record.